Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

AIM: To demonstrate that administering heparanase inhibitor PI-88 at 160 mg/d is safe and promising in reducing hepatocellular carcinoma (HCC) recurrence for up to 3 year following curative resection. METHODS: A total of 143 patients (83.1% of the 172 participants in the phase II study) participated...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Liu, Chun-Jen, Chang, Juliana, Lee, Po-Huang, Lin, Deng-Yn, Wu, Cheng-Chung, Jeng, Long-Bin, Lin, Yih-Jyh, Mok, King-Tong, Lee, Wei-Chen, Yeh, Hong-Zen, Ho, Ming-Chih, Yang, Sheng-Shun, Yang, Mei-Due, Yu, Ming-Chin, Hu, Rey-Heng, Peng, Cheng-Yuan, Lai, Kuan-Lang, Chang, Stanley Shi-Chung, Chen, Pei-Jer
Формат: Artigo
Язык:Inglês
Опубликовано: Baishideng Publishing Group Inc 2014
Предметы:
Observational Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4145780/
https://ncbi.nlm.nih.gov/pubmed/25170226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i32.11384
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы